[go: up one dir, main page]

PT3042658T - Medicinal composition improving leptin resistance - Google Patents

Medicinal composition improving leptin resistance

Info

Publication number
PT3042658T
PT3042658T PT14843063T PT14843063T PT3042658T PT 3042658 T PT3042658 T PT 3042658T PT 14843063 T PT14843063 T PT 14843063T PT 14843063 T PT14843063 T PT 14843063T PT 3042658 T PT3042658 T PT 3042658T
Authority
PT
Portugal
Prior art keywords
medicinal composition
leptin resistance
composition improving
improving leptin
resistance
Prior art date
Application number
PT14843063T
Other languages
Portuguese (pt)
Inventor
Akira C/O Kyoto University Kakizuka
Ken C/O Kyoto University Ebihara
Megumi C/O Kyoto University Abe
Chihiro C/O Kyoto University Ebihara
Original Assignee
Univ Kyoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kyoto filed Critical Univ Kyoto
Publication of PT3042658T publication Critical patent/PT3042658T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/655Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C07C245/10Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT14843063T 2013-09-04 2014-09-03 Medicinal composition improving leptin resistance PT3042658T (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013183265 2013-09-04

Publications (1)

Publication Number Publication Date
PT3042658T true PT3042658T (en) 2019-05-13

Family

ID=52628448

Family Applications (1)

Application Number Title Priority Date Filing Date
PT14843063T PT3042658T (en) 2013-09-04 2014-09-03 Medicinal composition improving leptin resistance

Country Status (8)

Country Link
US (1) US9931351B2 (en)
EP (1) EP3042658B1 (en)
JP (1) JP6378685B2 (en)
DK (1) DK3042658T3 (en)
ES (1) ES2708577T3 (en)
PL (1) PL3042658T3 (en)
PT (1) PT3042658T (en)
WO (1) WO2015033981A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12011438B2 (en) 2018-04-16 2024-06-18 Kyoto University Composition for protecting cardiomyocyte
JP7101982B2 (en) 2018-07-31 2022-07-19 国立大学法人京都大学 Pharmaceutical composition for the treatment of cerebral infarction
KR20220087499A (en) 2019-10-24 2022-06-24 고쿠리츠 다이가쿠 호진 교토 다이가쿠 Pharmaceutical composition for cartilage protection
JP7705649B2 (en) 2021-04-28 2025-07-10 国立大学法人京都大学 Composition for improving abnormalities in skin tissue
CN118434418A (en) 2021-12-24 2024-08-02 国立大学法人京都大学 Composition for improving heart function
KR20250093323A (en) * 2022-10-27 2025-06-24 가부시키가이샤 교토 소야쿠 겐큐쇼 Determination of naphthalene derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0679088T3 (en) 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonary delivery of active fragments of parathyroid hormone
CN1158290C (en) 1996-01-17 2004-07-21 诺沃挪第克公司 Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
IL133604A0 (en) 1997-07-16 2001-04-30 Novo Nordisk As Fused 1, 2, 4-thiadiazine derivatives, their preparation and use
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
WO2007041282A2 (en) 2005-09-29 2007-04-12 The Johns Hopkins University Methods and compositions for treatment of cystic fibrosis
PT2599771T (en) * 2010-07-30 2016-12-14 Univ Kyoto Naphthalene derivative
EP2623494B1 (en) 2010-09-30 2015-09-02 Daito Chemix Corporation Agent for treatment of eye diseases
BR112015001213A2 (en) 2012-07-20 2018-05-22 Cleave Biosciences Inc fused pyrimidines as p97 complex inhibitors
US9782420B2 (en) 2013-02-20 2017-10-10 Kyoto University Method for treating eye diseases

Also Published As

Publication number Publication date
JPWO2015033981A1 (en) 2017-03-02
WO2015033981A1 (en) 2015-03-12
PL3042658T3 (en) 2019-08-30
EP3042658A1 (en) 2016-07-13
ES2708577T3 (en) 2019-04-10
US9931351B2 (en) 2018-04-03
US20160303144A1 (en) 2016-10-20
DK3042658T3 (en) 2019-04-23
EP3042658B1 (en) 2019-01-16
EP3042658A4 (en) 2017-03-29
JP6378685B2 (en) 2018-08-22

Similar Documents

Publication Publication Date Title
IL286759A (en) Therapeutic methods and compositions
ZA201506487B (en) Therapeutic compounds and compositions
IL246377A0 (en) Oral pharmaceutical composition
GB201317286D0 (en) Composition and Use
SG11201508167PA (en) Therapeutic compositions and uses thereof
IL241254A0 (en) Pharmaceutical compositions comprising everolimus
ZA201403276B (en) Low dose pharmaceutical composition
EP3006525A4 (en) Asphalt-urethane composition
GB201318489D0 (en) Composition
SG11201510442TA (en) Oral composition
GB201317388D0 (en) Composition
GB201306984D0 (en) Composition
PT3042658T (en) Medicinal composition improving leptin resistance
GB201317196D0 (en) Composition
SG11201601477VA (en) Pharmaceutical composition
TWI562776B (en) Pharmaceutical composition and uses thereof
GB201307622D0 (en) Composition
SG11201506778QA (en) Plasticizing composition
GB201308933D0 (en) Paediatric composition
GB201301979D0 (en) New composition and use thereof
EP2977051A4 (en) Ginsenoside composition
GB201308502D0 (en) Composition
GB201301774D0 (en) Composition
IL244365A0 (en) Pharmaceutical composition
GB201318394D0 (en) Composition